Artigo

Low prevalence of human pegivirus 1 (HPgV-1) in HTLV-1 carriers from Bel?m, Par?, North Region of Brazil

Introduction - Human pegivirus 1 (HPgV-1) is a single-stranded, positive-sense RNA virus belonging to the Flaviviridae family with limited cause-effect evidence of the causation of human diseases. However, studies have shown a potential beneficial impact of HPgV-1 coinfection in HIV disease progress...

ver descrição completa

Autor principal: Lima, Ana Beatriz Figueiredo de
Outros Autores: S?, Keyla Santos Guedes de, Torres, Maria Karoliny da Silva, Soares, Luana da Silva, Resques, Hugo Reis, Azevedo, V?nia Nakauth, Feitosa, Rosimar Neris Martins, Monteiro, Jacqueline Cortinhas, Silva, Andrea Nazar? Monteiro Rangel da, Ribeiro, Andre Luis Ribeiro, Oliveira-Filho, Aldemir Branco de, Vallinoto, Antonio Carlos Rosario, Machado, Luiz Fernando Almeida
Grau: Artigo
Idioma: eng
Publicado em: Public Library of Science 2020
Assuntos:
Acesso em linha: http://patua.iec.gov.br//handle/iec/4091
Resumo:
Introduction - Human pegivirus 1 (HPgV-1) is a single-stranded, positive-sense RNA virus belonging to the Flaviviridae family with limited cause-effect evidence of the causation of human diseases. However, studies have shown a potential beneficial impact of HPgV-1 coinfection in HIV disease progression. Human T lymphotropic virus-1 (HTLV-1) is a retrovirus known for causing diseases, especially in muscle and white blood cells, in approximately 5% of patients. Thus, this study aimed to investigate the potential effects of an HPgV-1 infection in patients carrying HTLV-1 in the state of Par? in the North Region of Brazil. Methods - A group of HTLV-1 carriers was compared to healthy controls. Blood samples were collected, data from medical regards were collected, and a questionnaire was administered. HPgV-1 and HTLV-1 positivity was determined by quantitative polymerase chain reaction (qRT-PCR). The data were analyzed to correlate the effects of HPgV-1 coinfection in HTLV-1 carriers. Results - A total of 158 samples were included in the study: 74 HTLV-1-positive patients (46,8%) and 84 healthy controls (53,2%). The overall HPgV-1 positivity rate was 7.6% (12/158), resulting in a prevalence of 5.4% (4/74) and 9.5% (8/84) in HTLV-1 carriers and healthy controls, respectively. No significant differences were found when comparing any clinical or demographic data between groups. Conclusion - This study indicated that the prevalence of HPgV-1 infection is low in HTLV-1 carriers in Bel?m, Par?, and probably does not alter the clinical course of HTLV-1 infection, however, further studies are still needed.